Abstract
Purpose
To evaluate the retention of intravitreal triamcinolone acetonide (TA) particles and the efficacy of TA therapy for patients with cystoid macular edema in branch retinal vein occlusion (BRVO) or diabetic macular edema (DME). We monitored the TA particles until absorption from the vitreous cavity was complete. The correlation between the intravitreal retention time of TA and its efficacy was evaluated based on central macular thickness (CMT).
Results
The intravitreal TA retention time was a mean 141.8 ± 139.6 days in BRVO patients and 114.5 ± 59.6 days in DME patients. Patient age and retention time were negatively correlated (r = −0.46; P = 0.013). At 6 months posttreatment the mean CMT decreased from 544.1 ± 143.7 to 322.4 ± 131.9 μm in BRVO patients and from 454.5 ± 119.0 to 371.2 ± 209.4 μm in DME patients. Retention time and CMT reduction were positively correlated in BRVO patient (r = 0.56, P = 0.02) but not in DME patients (P = 0.06).
Conclusions
Intravitreal TA reduced the CMT in BRVO and DME patients over 6 months. The retention time was longer in younger individuals. The efficacy of the therapy depended on the intravitreal TA retention time observed clinically in BRVO patients. Biomicroscopic examination of intravitreal TA is useful for evaluation of its efficacy.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
The Branch Vein Occlusion Study Group. Argon laser photocoagulation for macular edema in branch retinal vein occlusion. Am J Ophthalmol 1984;98:271–282.
Early Treatment Diabetic Retinopathy Study Research Group. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Arch Ophthalmol 1985;103:1796–1806.
Early Treatment Diabetic Retinopathy Study Research Group. Early Photocoagulation for diabetic retinopathy. Early Treatment Diabetic Retinopathy Study report number 9. Ophthalmology 1991;98:766–785.
Lee CM, Olk RL. Modified grid laser photocoagulation for diffuse diabetic macular edema. Long-term visual results. Ophthalmology 1991;98:1594–1602.
Antcliff RJ, Spalton DJ, Stanford MR, Graham EM, Ffytche TJ, Marshall J. Intravitreal triamcinolone for uveitic cystoid macular edema: an optical coherence tomography study. Ophthalmology 2001;108:765–772.
Jonas JB, Akkoyoun I, Kampetter B, Kreissig I, Degenring RF. Branch retinal vein occlusion treated by intravitreal triamcinolone acetonide. Eye 2005;19:65–71.
Lee H, Shah GK. Intravitreal triamcinolone as primary treatment of cystoid macular edema secondary to branch retinal vein occlusion. Retina 2005;25:551–555.
Krepler K, Ergun E, Sacu S, et al. Intravitreal triamcinolone acetonide in patients with macular oedema due to branch retinal vein occlusion: a pilot study. Acta Ophthalmol Scand 2005;83:600–604.
Jonas JB, Sofker A. Intraocular injection of crystalline cortisone as adjunctive treatment of diabetic macular edema. Am J Ophthalmol 2001;132:425–427.
Martidis A, Ducker JS, Greenberg PB, et al. Intravitreal triamcinolone for refractory diabetic macular edema. Ophthalmology 2002;109:920–927.
Beer PM, Bakri SJ, Singh RJ, Liu W, Peters GB 3rd, Miller M. Intraocular concentration and pharmacokinetics of triamcinolone acetonide after a single intravitreal injection. Ophthalmology 2003;110:681–686.
Armaly MF. The heritable nature of dexamethasone-induced ocular hypertension. Arch Ophthalmol 1966;75:32–35.
Park CH, Jaffe GJ, Fekrat S. Intravitreal triamcinolone acetonide in eyes with cystoid macular edema associated with central retinal vein occlusion. Am J Ophthalmol 2003;136:419–425.
Antcliff RJ, Spalton DJ, Stanford MR, Granham EM, Ffytche TJ, Marshall J. Intravitreal triamcinolone for uveitic cystoid macular edema: an optic coherence tomography study. Ophthalmology 2001;108:765–772.
Jonas JB, Kreissig I, Degenring RF. Intravitreal triamcinolone acetonide for pseudophakic cystoid macular edema. Am J Ophthalmol 2003;136:384–386.
Spandau UHM, Derse M, Schmitz-Valkenberg P, Papoulis C, Jonas JB. Dosage dependency of intravitreal triamcinolone acetonide as treatment for diabetic macular oedema. Br J Ophthalmol 2005;89:999–1003.
Chin HS, Park TS, Moon YS, Oh JH. Difference in clearance of intravitreal triamcinolone acetonide between vitrectomized and nonvitrectomized eyes. Retina 2005;25:556–560.
Audren F, Tod M, Massin P, et al. Pharmacokinetic-pharmacodynamic modeling of the effect of triamcinolone acetonide on central macular thickness in patients with diabetic macular edema. Invest Ophthalmol Vis Sci 2004;45:3435–3441.
Inoue M, Takeda K, Morita K, Yamada M, Tanigawara Y, Oguchi Y. Vitreous concentrations of triamcinolone acetonide in human eyes after intravitreal triamcinolone or subtenon injection. Am J Ophthalmol 2004;138:1046–1048.
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Kogure, A., Ohkoshi, K., Kogure, S. et al. Efficacy and retention times of intravitreal triamcinolone acetonide for macular edema. Jpn J Ophthalmol 52, 122–126 (2008). https://doi.org/10.1007/s10384-007-0513-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10384-007-0513-7